A5041867256- Smoking Behavior and Cessation
- Nicotinic Acetylcholine Receptors Study
- Obesity, Physical Activity, Diet
- Behavioral Health and Interventions
- Biochemical Analysis and Sensing Techniques
- Consumer Attitudes and Food Labeling
- Circadian rhythm and melatonin
- Nutritional Studies and Diet
- Coffee research and impacts
- Global Public Health Policies and Epidemiology
- Eating Disorders and Behaviors
- Genomics, phytochemicals, and oxidative stress
- Youth, Drugs, and Violence
- Health Literacy and Information Accessibility
- Pharmacogenetics and Drug Metabolism
- Heart Rate Variability and Autonomic Control
- Antioxidant Activity and Oxidative Stress
- Fatty Acid Research and Health
- Sodium Intake and Health
- Blood Pressure and Hypertension Studies
- Asthma and respiratory diseases
Universidade de São Paulo
2015-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2018-2024
Instituto do Coração
2024
Hospital do Coração
2018
1. Teo KK, Ounpuu S, Hawken et al. Tobacco use and risk of myocardial infarction in 52 countries the INTERHEART study: a case-control study. Lancet. 2006;368(9536):647-658. doi:10.1016/S0140-6736(06)69249-0 CrossRef Google Scholar
// Jaqueline Scholz 1 , Paulo Caleb Junior Lima Santos 2 Carolina Giusti Buzo 3 Neuza Helena Moreira Lopes 3,4 Tania Marie Ogawa Abe Patricia Viviane Gaya Humberto Pierri Clarice Amorim 5 and Alexandre Costa Pereira Smoking Cessation Program Department, Heart Institute (InCor), University of São Medical School, Paulo, Brazil Laboratory Genetics Molecular Cardiology, Cardio Geriatric Clinical Unit, 4 Fleury Group, Oregon State University, Corvallis, OR, USA Correspondence to: Scholz, email:...
The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment nicotine dependence. In context personalized medicine, aims this study were to evaluate whether cholinergic alpha 2 (CHRNA2), 3 (CHRNA3), 5 (CHRNA5) beta (CHRNB3) polymorphisms dependence severity, investigate possible pharmacogenetics markers cessation treatment.This cohort enrolled 1049 patients who received...
Smoking is the most important reversible cardiovascular risk factor. It well established that quitting smoking reduces coronary events. However, on several occasions, safety of cessation drugs has been questioned. Our goal to evaluate effects blood pressure and heart rate in patients from a service cardiology hospital.We examined PAF database (Smoking Cessation Assistance Program database) between January 2008 March 2014. We analyzed data 900 who were compliant with treatment (50.5% male,...
Background: Smoking is the leading cause of preventable death worldwide. It responsible for several types cancer, cardiovascular diseases, and diseases reproductive system, among others. Therefore, advances in research are increasingly necessary order to make smoking cessation treatment more effective. Some studies have investigated association nicotine metabolite ratio (NMR) with general characteristics outcomes. In present study, main aim was evaluate NMR patients from an Assistance...
Evaluating the cost-effectiveness of a first-line smoking cessation drug using an electronic medical record system is very important for defining best decision-making tree to use in Brazilian National Health System (SUS). This study aimed evaluate cost effectiveness varenicline compared with bupropion and nicotine replacement therapy (NRT) (gum patches) program. We included 940 patients admitted Smokers had access consultations prescription therapies (NRT — patch gum), bupropion,...
1. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885-1906. doi:10.1016/S0140-6736(17)30819-X CrossRef Google Scholar
INTRODUCTION Smoking cessation is the best strategy for reducing tobacco-related morbimortality.The goal of this randomized controlled trial was to test whether using genetically favorable markers choose a smoking drug treatment (precision medicine) superior most effective (varenicline) in terms abstinence rates.Additionally, combination therapy tested when monotherapy failed.METHODS This partially blind, single-center study (1:1) 361 participants into two major groups.In genetic group...
Introduction: Smoking is considered the leading cause of preventable morbidity and mortality worldwide. Studies have sought to identify predictors response smoking cessation treatments. The aim this study was analyze a possible association target gene expression for with varenicline. Methods: We included 74 smokers starting treatment Gene analysis performed through custom RT² Profiler qPCR array assay, including 17 genes. Times sample collection were before start therapy (T0) two weeks (T2)...
Introduction: Varenicline effectively helps smokers quit by reducing withdrawal symptoms and blocking the reward of smoking. However, most quitters return to smoking within 1 year. “Cue-restricted smoking” is a behavioral technique designed increase rates asking attempting restrict standing position, while alone, in an isolated area facing wall, with cigarette as only stimulus. Hypothesis: We compared effectiveness cue-restricted cessation advice versus standard target date from day 8...